- Home
- AVIR vs IMMR Comparison
AVIR vs IMMR Comparison
Compare AVIR & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- IMMR
- Stock Information
- Founded
- AVIR 2012
- IMMR 1993
- Country
- AVIR United States
- IMMR United States
- Employees
- AVIR N/A
- IMMR N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- IMMR Computer peripheral equipment
- Sector
- AVIR Health Care
- IMMR Technology
- Exchange
- AVIR Nasdaq
- IMMR Nasdaq
- Market Cap
- AVIR 273.7M
- IMMR 237.6M
- IPO Year
- AVIR 2020
- IMMR 1999
- Fundamental
- Price
- AVIR $2.85
- IMMR $7.74
- Analyst Decision
- AVIR Hold
- IMMR Strong Buy
- Analyst Count
- AVIR 1
- IMMR 2
- Target Price
- AVIR $6.88
- IMMR $12.25
- AVG Volume (30 Days)
- AVIR 247.5K
- IMMR 472.8K
- Earning Date
- AVIR 03-06-2025
- IMMR 03-12-2025
- Dividend Yield
- AVIR N/A
- IMMR 4.90%
- EPS Growth
- AVIR N/A
- IMMR 57.07
- EPS
- AVIR N/A
- IMMR 2.04
- Revenue
- AVIR N/A
- IMMR $163,133,000.00
- Revenue This Year
- AVIR N/A
- IMMR $988.71
- Revenue Next Year
- AVIR N/A
- IMMR $288.32
- P/E Ratio
- AVIR N/A
- IMMR $3.80
- Revenue Growth
- AVIR N/A
- IMMR 338.21
- 52 Week Low
- AVIR $2.75
- IMMR $7.06
- 52 Week High
- AVIR $4.15
- IMMR $13.94
- Technical
- Relative Strength Index (RSI)
- AVIR 36.06
- IMMR 47.09
- Support Level
- AVIR $2.90
- IMMR $7.49
- Resistance Level
- AVIR $3.29
- IMMR $8.11
- Average True Range (ATR)
- AVIR 0.12
- IMMR 0.25
- MACD
- AVIR -0.03
- IMMR 0.03
- Stochastic Oscillator
- AVIR 8.33
- IMMR 57.95
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.